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PMLThe serine/threonine kinase HIPK2 regulates gene expression programs controlling differentiation and cell
death. HIPK2 localizes in subnuclear speckles, but the structural components allowing this localization are not
understood. A point mutation analysis allowed mapping two nuclear localization signals and a SUMO
interaction motif (SIM) that also occurs in HIPK1 and HIPK3. The SIM binds all three major isoforms of SUMO
(SUMO-1–3), while only SUMO-1 is capable of covalent conjugation to HIPK2. Deletion or mutation of the SIM
prevented SUMO binding and precluded localization of HIPK2 in nuclear speckles, thus causing localization of
HIPK2 to the entire cell. Functional inactivation of the SIM prohibited recruitment of HIPK2 to PML nuclear
bodies and disrupted colocalization with other proteins such as the polycomb protein Pc2 in nuclear speckles.
Interaction of HIPK2 with Pc2 or PML in intact cells was largely dependent on a functional SIM in HIPK2,
highlighting the relevance of SUMO/SIM interactions as a molecular glue that serves to enhance protein/
protein interaction networks. HIPK2 mutants with an inactive SIM showed changed activities, thus revealing
that non-covalent binding of SUMO to the kinase is important for the regulation of its function.+49 641 9947589.
i-giessen.de (M.L. Schmitz).
, National Institute of Diabetes
f Health, Bethesda, MD 20892,
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Post-translational modiﬁcation by attachment of SUMO (small
ubiquitin-like modiﬁer) to lysines plays an important role for the
regulation of a wide range of cellular functions. The family of
human SUMO proteins comprises three well-characterized paralogues,
SUMO-1 to SUMO-3, while SUMO-4 has only been proposed based on
DNAsequence analysis [1].Within the groupof SUMOproteins, SUMO-2
and SUMO-3 are highly homologous and share 97% sequence identity.
The distinct biological functions of SUMO-1 and SUMO-2/3 rely on
sequence differences in the N-termini, which allow SUMO-2/3 to
generate polymers, while SUMO-1 occurs only in a monomeric form
[2,3]. SUMO proteins can be conjugated covalently to target lysines, but
they also have the ability to bind to target proteins in a non-covalent
manner via so-called SUMO interaction motifs (SIMs). They typically
consist of a hydrophobic core, which is often ﬂanked by acidic residues
[4,5]. SIMs allowbinding to SUMOproteins and thus can act as a docking
motif to enhance or specify the interaction with other SUMOylatedproteins. Intriguingly, mutation of lysines used for covalent attachment
of SUMO is scarcely associated with a clear phenotype, while mutation
of SIMs often causes drastic changes. This highlights the importance of
SUMO/SIM interactions, as illustrated by numerous examples showing
their relevance for DNA replication, assembly of nuclear bodies, the
replicative stress response, and regulation of thymine DNA glycosylase
[1,6].
Among thenumerous SUMOsubstrates is alsoHIPK2(homeodomain-
interactingprotein kinase2), anevolutionary conserved serine/threonine
kinase [7,8]. HIPK2 is activated in response to DNA-damaging or
morphogenic signals and accordingly HIPK2-guided gene expression
programs trigger differentiation and development or alternatively
apoptosis [9]. HIPK2 regulation employs several mechanisms such as
control of its stability by the degradative ubiquitination or caspase-
mediated cleavage of the autoinhibitory domain, thus generating HIPK2
fragments with higher activity [10,11]. HIPK2 functions as a general
regulator of gene expression but also as a kinase that phosphorylates and
regulates transcription factors such as p53 and IPF1/PDX (insulin
promoter factor-1/pancreatic duodenal homeobox-1) [12–14]. Besides
its ability to phosphorylate transcription factors, HIPK2 can also control
the abundance of some transcription factors as exempliﬁed by the ability
of HIPK2 to repress the expression of hypoxia-inducible factor (HIF) [15].
Under hypoxic conditions, HIPK2-mediated repression of HIF and many
of its target genes is relieved by ubiquitin/proteasome-dependent
degradation of HIPK2 on a pathway employing the ubiquitin E3 ligase
Siah2 (seven-in-absentia) [16]. HIPK2 belongs to a small family of
kinases, which includes HIPK1, HIPK2, and HIPK3 and also the more
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Fig. 1. Identiﬁcation of NLS sequences in HIPK2. (A) Schematic representation of HIPK2 domains. The sequence of each putative NLS is given, themutated amino acids are indicated in
bold. (B) U2OS cells were transfected to express Flag-tagged HIPK2wild-type and point mutated versions thereof as indicated. The intracellular localization of HIPK2was detected by
indirect immunoﬂuorescence, nuclear DNA was stained with DAPI. Representative pictures are displayed. (C) U2OS cells were transfected to express GFP-tagged HIPK2 or a kinase
inactive point mutant thereof. Cells expressing wild-type HIPK2 were incubated with the HIPK2 inhibitor D-115893 (10 nM) overnight as shown, and localization of HIPK2 was
revealed by the intrinsic ﬂuorescence of GFP. Chromosomal DNA was stained with DAPI.
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show only limited homology, while the kinase domains show N90%
identity. This is also reﬂected by a certain degree of functional
redundancy, as mice deﬁcient for the Hipk1 or Hipk2 genes are viable
whereas double deﬁcient mice die within the ﬁrst 2 weeks after
fertilization [17]. However, most functions are non-redundant, as single
HIPK2 knockout mice develop more skin tumors and are subjected to
faster disease progression than wild-type mice after two-stage skin
carcinogenesis treatment [18].
HIPK2 typically localizes to subnuclear speckles termed HIPK
domains or also nuclear deposition sites (NUDES) [19,20]. A minor
fraction of the kinase colocalizes with the promyelocytic leukemia
(PML) tumor suppressor protein in PML nuclear bodies (PML-NBs).
Some cells also show HIPK2 localizing more diffusely in the
nucleoplasm and also the cytoplasm [20,21]. HIPK2 is composed of
an N-terminal kinase domain, which is preceded by a SUMO
attachment site at lysine 25 [22,23]. The SUMO modiﬁcation of
HIPK2 employs the SUMO E3 ligase Pc2 (also known as CBX4),
which is a member of the polycomb (PcG) class of proteins [24]. The
kinase domain is followed by a region allowing interactions with
homeodomain transcription factors and a variety of further proteins.
The C-terminal portion of the kinase harbors an autoinhibitory
domain between position 935 and 1050, which partially overlaps
with a speckle retention signal (SRS, between amino acids 860 and
967) [25]. Previous deletion experiments have shown that HIPK2
variants lacking the SRS fail to localize to HIPK domains, but the
molecular mechanisms explaining this effect are not known.
In this study, we have systematically analyzed the sequence
elements in HIPK2mediating its localization (I) in the nucleus and (II)
in nuclear bodies. While nuclear localization employs two nuclear
localization sequences (NLS), retention in nuclear bodies and
recruitment to PML-NBs was critically dependent on a functional
SIM contained in the SRS. Functional studies revealed a role of the SIM
for protein/protein interactions and HIPK2 activity.2. Materials and methods
2.1. Cell culture and transfections
HEK293T cells and U2OS cells were grown in DMEM containing
10% FCS and 1% (w/v) penicillin/streptomycin at 37 °C and 5% CO2.
The p53-deﬁcient H1299 cells were cultivated in supplemented RPMI
medium. Cells were plated out 1 day prior to transfection, which was
done using Rotifect (Roth) according to the manufacturer's instruc-
tions. DNA amounts in each transfection were kept constant upon
addition of empty expression vector.
2.2. Antibodies and plasmids
2.2.1. Antibodies, plasmids, and reagents
Antibodies recognizing Flag (M2) and β-tubulin (tub 2.1) (Sigma),
anti-HA (3F10) and anti-GFP (7.1 and 13.1) (Roche Applied Science),
anti-T7 (Novagen), anti-p53 (DO-1), and anti-PML (PG-M3) (Santa
Cruz) were from the indicated companies. The phospho-p53 (ser46)
and control IgG antibodies were from Cell Signaling Technology, and
anti-phospho-PML [26] and the anti-phospho-Siah2 [16] antibodies
have been described. Expression vectors for Flag-HIPK2, Flag-HIPK2
K221A, GFP-HIPK2, p53, GFP-SUMO-1, PML-IV [13], epitope-tagged
Pc2 [27], HA-Siah2 [16], IPF1/PDX [14], and GFP-Hp66ß [28] were
published previously. Also the reporter plasmids p53-Luc [13] and 5x
P1-Luc [14] were described. The vectors encoding GFP-SUMO-2 and-3
are kind gifts from Hans Will (Heinrich Pette Institut Hamburg),
vectors for GST-SUMO fusion proteins were from Ivan Dikic
(Frankfurt), and Flag-SUMO-1-GG/AA was obtained from Stefan
Müller (Martinsried). The various point mutants were generated
using QuickChange® site-directed Mutagenesis Kit (Stratagene), and
deletion mutants were generated by PCR cloning. The authenticity of
the constructs was veriﬁed by DNA sequencing. Details on the cloning
strategies can be obtained from the authors upon request. The HIPK2
286 L. de la Vega et al. / Biochimica et Biophysica Acta 1813 (2011) 283–297inhibitor D-115893 was a kind gift from Æterna Zentaris (Frankfurt,
Germany).2.3. Cell lysis protocols and luciferase reporter assays
Soluble fractions were obtained after lysis of cells in NP-40 buffer
(20 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM phenylmethylsulfonyl-
ﬂuoride, 10 mM NaF, 0.5 mM sodium orthovanadate, leupeptine
(10 μg/ml), aprotinin (10 μg/ml), 1% (v/v) NP-40, and 10% (v/v)
glycerol). After centrifugation of lysates at 4 °C, the supernatant was
either mixed with SDS sample buffer and further analyzed by
immunoblotting or used for determination of luciferase activity in a
Berthold LB 9507 luminometer. Protein SUMOylation was tested after
directly lysing an aliquot of the cells in 1× SDS sample buffer and
soniﬁcation.Fig. 2. Identiﬁcation of a functional SIM in HIPK2. (A) The indicated HIPK2 construc
immunoﬂuorescence. (B) The sequences corresponding to the putative SIM in all HIPK forms
stars, homologous, and related amino acids are indicated. The lower part shows the hydrop
the block of acidic amino acids are highlighted by writing in bold. (C) HIPK2 binds non-co
Flag-HIPK2 was tested for interaction with bacterially produced GST and GST–SUMO-1-3
(WB) displaying the input material and the eluates, the lower part shows the Coomassie2.4. Coimmunoprecipitation and Western blotting
For coimmunoprecipitation experiments, cells were washed in
phosphate-buffered saline (PBS) and incubated in the presence of
0.5 mM of the membrane-permeable crosslinker dimethyl-3-3′-
dithiobispropionimidate 2-HCl (Pierce) as previously described [24].
Cellswere lysed in IPbuffer (50 mMHepes pH7.5, 50 mMNaCl, 1% (v/v)
Triton X-100, 2 mM EDTA, 10 mM sodium ﬂuoride, 0.5 mM sodium
orthovanadate, leupeptine (10 μg/ml), aprotinin (10 μg/ml), and 1 mM
PMSF), followed by a sonication step. Cell debris was removed by
centrifugation, and extracts were precleared with A/G sepharose. The
supernatants weremixed with 2 μg of precipitating antibodies together
with 25 μl of protein A/G sepharose. Tubes were rotated for 2 h on a
spinning wheel at 4 °C. The immunoprecipitates were washed 5× with
IP buffer and eluted by boiling in 1× SDS sample buffer. Equal amounts
of proteinwere separated by SDS-PAGE, followed by semidry blotting tots were expressed in U2OS cells and analyzed for HIPK2 localization by indirect
and the positions of the amino acids are indicated. Identical amino acids are marked by
hobic SIM consensus sequence, x stands for any amino acid. The hydrophobic core and
valently to GST–SUMO-1-3 in vitro. Total cell extract from cells transfected to express
proteins by pull-down experiments as shown. The upper part shows a Western blot
-stained GST fusion proteins used for this experiment.
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membrane with milk powder, primary antibodies were added.
Appropriate secondary antibodies coupled to horseradish peroxidase
were detected by enhanced chemiluminescence.2.5. GST pull-down assays
Recombinant GST fusion proteins were produced in Escherichia coli
BL21 and puriﬁed on GSH-coupled beads by standard methods. The
eluates were dialyzed against PBS buffer and frozen in aliquots. HIPK2
and its derivateswere produced by expression in transiently transfected
HEK293T cells, followed by cell lysis. Ten percent of the lysate was used
for the input control,while the remaining extractwasdivided to beused
for incubation with 4 μg of GST or the GST fusion proteins, respectively.
Binding occurred at 4 °C for 3 h andGSH-coupled sepharose beadswere
added for another hour. After extensive washing in PBS, bound proteins
were eluted with 1× SDS sample buffer and subsequent boiling for
5 min. Eluates were further analyzed by denaturing SDS-PAGE andFig. 3. Characterization of a functional SIM in HIPK2. (A) Schematic display of the wild-type H
acids. (B) Lysates of HEK293T cells transfected to express the indicated HIPK2 proteins wer
shows the Western blot revealing the bound HIPK2 protein and the Coomassie-stained inp
(C) Localization of the indicated HIPK2 variants was analyzed in U2OS cells by immunoﬂuoWestern blotting, while the recombinant GST proteins were controlled
by SDS-PAGE and Coomassie staining.2.6. Immunoﬂuorescence
Cells were grown on coverslips and transfected with indicated
vectors. The next day, cells were washed once with PBS and ﬁxed for
5 min at−20 °C in methanol/aceton (1:1). Dried cells were blocked for
30 min at room temperature in phosphate-buffered saline containing
10% (v/v) goat serum. Cells were incubated for 1 h with primary
antibodies at room temperature, washed extensively with PBS,
and incubated for another 45 min with appropriate ﬂuorochrome-
conjugated secondary antibodies. Chromosomal DNAwas visualized by
DAPI staining. Stained cells weremounted on glass slides and examined
using an inverted Nikon Eclipse 2000E microscope. Dying or mitotic
cells and also cells expressing aberrantly high levels of theproteinswere
not analyzed. All immunoﬂuorescence data are representative for N80%
of interphase cells.IPK2 protein and the mutants either lacking a SIM or changed in the underlined amino
e tested for binding to GST or GST–SUMO-1 by pull-down experiments. The upper part
ut control. The lower part shows the HIPK2 variants as detected by immunoblotting.
rescence, nuclear DNA was stained with DAPI.
Fig. 3 (continued).
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3.1. Mapping of the NLS in HIPK2
All results on the structural requirements dictating intracellular
localization of HIPK2 are based on the use of deletion mutants lacking
signiﬁcant parts of the protein [25]. These mutants provide valuable
information but, on the other hand, do not allow the identiﬁcation of
the involved short signal sequences and may also affect the overall
structure or conformation of the kinase. In order to identify the NLS
sequence(s) responsible for the mainly nuclear localization of HIPK2,
the amino acid sequence was analyzed for the occurrence of clusters
containing basic amino acids typical for NLS sequences [29]. We
identiﬁed 4 such clusters, as schematically shown in Fig. 1A. Their
possible contribution for nuclear localization of HIPK2 was tested
upon mutation of basic amino acids contained in these clusters to
alanine and analysis of HIPK2 localization by immunoﬂuorescence
(Fig. 1B). Mutation of R126 had no inﬂuence on HIPK2 localization to
nuclear HIPK domains, while mutation of R546 still allowed the
occurrence of HIPK2 in the nucleus but slightly increased the
percentage of cells with cytosolic HIPK2. Changing lysine 796 alone
to alanine caused no alteration of HIPK2 localization, while additional
mutation of lysine 798 resulted in the localization of HIPK2 within the
entire cell, thus identifying this sequence as an NLS. In addition,
mutation of either R826 to alanine or K828 to a negatively charged
amino acid resulted in prominent loss of nuclear localization, thusrevealing this region as a second NLS. In summary, these experiments
allowed to identify two NLS for HIPK2 consisting of the sequences
795-RKSK-798 (NLS1) and 825-KRVK-828 (NLS2). Early work on
HIPK2 showed a mainly nucleoplasmic localization of the HIPK2
kinase inactive point mutant HIPK2 K221A [8]. Also other HIPK2
mutants with absent kinase activity localize to the nucleoplasm
(Supplementary Fig. 1), thus revealing the general importance of the
kinase function for localization to nuclear bodies. These results also
raise the question whether the inactivation of the kinase function of
the wild-type kinase already existing in nuclear speckles can
be affected by a small molecule kinase inhibitor. To address this
question, we took advantage from the availability of the HIPK2
inhibitor D-115893, which inhibits HIPK2 in vitro (data not shown)
and HIPK2-dependent functions such as p53 serine 46 phosphoryla-
tion (Supplementary Fig. 2). The addition of nanomolar amounts of
D-115893 resulted in a drastic loss of nuclear HIPK2 localization
(Fig. 1C). These results collectively show that ongoing kinase activity
together with a bipartite NLS is required for the occurrence of HIPK2
in the nucleus.
3.2. Identiﬁcation and functional characterization of a SIM in HIPK2
We observed that a HIPK2 mutant lacking the region between 786
and 886 lost its ability to localize to speckles (Fig. 2A), suggesting the
relevance of the deleted region for proper localization. Reinspection of
the sequence allowed to identify the sequence 880-VITI-883, which
Fig. 4. The HIPK2 SIM is required for uptake into PML-NBs and binding to PML-IV. (A) U2OS cells were transfected to express the PML isoform PML-IV along with different HIPK2
forms as shown. The proteins were detected with Cy3 and Cy5-conjugated secondary antibodies, the merge reveals areas of overlapping localization in yellow. (B) The experiment
was done as in (A) with the exception that different HIPK2 constructs were used. (C) PML-IV and the indicated forms of Flag-tagged HIPK2 were coexpressed in HEK293T cells as
shown. Interacting proteins were crosslinked for 30 min to preserve protein/protein interactions occurring in intact cells. After removal of the crosslinker and quenching, cells were
lysed and subjected to immunoprecipitation (IP) using anti-Flag antibodies. The precipitates and input controls were analyzed by immunoblotting. (D) Cells were transfected to
express PML-IV along with HIPK2wild-type ormutants thereof at the indicated combinations. After 36 h, cells were harvested and cell extracts were analyzed by immunoblotting for
the occurrence and phosphorylation of the indicated proteins and for tubulin as a loading control.
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[6]. As this sequence is ﬂanked by a patch of 6 acidic amino acids
(Fig. 2B), this region is a high-probability candidate for a SIM. To test
binding of HIPK2 to the three SUMO isoforms, pull-down assays were
performed. Bacterially expressed and puriﬁed GST–SUMO-1, GST–
SUMO-2, and GST–SUMO-3 efﬁciently captured HIPK2 (Fig. 2C),
showing that all major SUMO isoforms have the ability to interact
with this kinase. To investigate the relevance of the putative SIM for
SUMO binding, HIPK2mutants were produced that either lack the SIM
or were mutated in order to target either the hydrophobic patch
(HIPK2 M1) or the block of acidic amino acids (HIPK2 M2), as
schematically displayed in Fig. 3A. GST pull-down experiments
revealed that deletion or mutation of the SIM completely destroyed
the ability of HIPK2 to interact with SUMO (Fig. 3B), thus identifyingthe sequence between 880 and 890 as a functional SIM. The HIPK2
mutants either lacking the SIM or containing mutated versions of the
hydrophobic or the acidic patch had lost the ability to localize in
nuclear domains and were found throughout the cell (Fig. 3C).
3.3. The HIPK2 SIM is required for recruitment to PML-NBs
In unstressed cells, only a minor fraction of HIPK2 colocalizes with
PML-NBs, while DNA damage increases the colocalization of both
proteins and allows for HIPK2-mediated phosphorylation of PML at
serines 8 and 38. The PML protein occurs in differentially spliced
forms exerting different functions, as, for example, only the splice
variant PML-IV promotes senescence in human diploid ﬁbroblasts
[30]. PML-IV localizes in nuclear speckles (Supplementary Fig. 3) and
Fig. 5. SUMO/SIM interactions contribute to Pc2 binding of HIPK2. (A) Schematic model summarizing the potential contribution of SUMO/SIM association for the formation of
intermolecular (upper) and intramolecular (lower) interactions. (B) T7-tagged Pc2 and the indicated Flag-tagged HIPK2 variants were coexpressed in U2OS cells and analyzed for
intracellular localization by immunoﬂuorescence. (C) T7-tagged Pc2 and HIPK2 wild-type andmutant proteins were coexpressed in HEK293T cells and analyzed by crosslinking and
coimmunoprecipitation as shown. (D) Cells were transfected to express HIPK2 along with GFP-SUMO-1 or a SUMO-1 variant defective for covalent attachment to a target lysine
(SUMO-1 GG/AA). Intracellular localization of the proteins was analyzed by immunoﬂuorescence.
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whether the SIM in HIPK2 is required for efﬁcient uptake of the kinase
in PML-NBs. To address this question, HIPK2 or mutant versions of the
kinase were coexpressed along with PML-IV. While the wild-type
kinase was efﬁciently recruited into PML-NBs, all mutants either
lacking the entire SIM or mutated in the hydrophobic or acidic patch
were not enriched in PML-NBs (Fig. 4A). Using a similar experimental
approach, we also tested PML-NB recruitment of a HIPK2 fragment
that is generated during caspase-dependent cleavage of HIPK2 (HIPK2
1-977) or a HIPK2 variant with a mutated NLS as exempliﬁed by
HIPK2 R826A with a defect NLS2. Both mutants could be largely
recruited to PML-NBs, although a small but signiﬁcant fraction of
HIPK2 R826A stayed in the cytosol (Fig. 4B). The impact of the SIM on
interaction between HIPK2 and PML was directly addressed by
coimmunoprecipitation experiments. These experiments require
crosslinking of the interacting proteins in intact cells, as SUMO
modiﬁcation is quickly lost during standard lysis conditions [1].
HEK293T cells were transfected to express PML-IV along with HIPK2
or HIPK2 ΔSIM. Cells were treated with a membrane-permeable
crosslinker to allow covalent coupling of proteins occurring in very
close proximity, followed by a coimmunoprecipitation experiment.
While the wild-type form of HIPK2 was found in association with
PML-IV, the deletion of the HIPK2 SIM largely precluded HIPK2/PML-IV
binding (Fig. 4C).3.4. Pc2 binding to HIPK2 largely depends on a functional SIM
It was then interesting to test the importance of NLS and SIM
sequences for the ability of HIPK2 to phosphorylate the PML protein.
To address this question, PML-IV was coexpressed with HIPK2 and
various mutants defect in SUMO binding or nuclear localization,
followed by analysis of PML-IV phosphorylation using a phospho-
speciﬁc antibody (Fig. 4D). The wild-type kinase induced PML
phosphorylation, while the NLS mutant HIPK2 R826A showed an
impaired PML phosphorylation. The HIPK2 ΔSIM mutant and the
HIPK2 K25A mutant harboring a mutation in the covalent SUMO
attachment site showed an intact PML phosphorylation despite their
reduced colocalization with PML.
SUMO/SIM interactions play an important role for the control of
protein/protein interaction afﬁnities [31]. These interactions can
occur in an intermolecular and/or intramolecular fashion as schemat-
ically displayed in Fig. 5A. The contribution of the SUMO/SIM system
in HIPK2 for intermolecular binding was investigated for the Pc2
protein, as it also binds covalently and non-covalently to SUMO
[32,33] and serves as a SUMO E3 ligase for HIPK2 [24]. The
colocalization between both proteins was studied by immunoﬂuo-
rescence after coexpression of Pc2 with either wild-type HIPK2 or
various mutants. While the non-SUMOylatable mutant HIPK2 K25A
still colocalized with Pc2, deletion of the HIPK2 SIM or mutation of
293L. de la Vega et al. / Biochimica et Biophysica Acta 1813 (2011) 283–297NLS2 resulted in a strongly reduced colocalization (Fig. 5B), showing
that the SIM of HIPK2 is of central relevance for colocalization with
Pc2. The role of the HIPK2 SIM for association with Pc2 was
investigated by crosslinking and coimmunoprecipitation experiments
in cells transfected to express T7-tagged Pc2 along with HIPK2, HIPK2
K25A, or HIPK2 ΔSIM. These experiments revealed that Pc2 binding of
the non-SUMOylatable HIPK2 K25Amutant was only slightly reduced,
while deletion of the SIM strongly impaired the interaction with Pc2
(Fig. 5C). These data highlight the relevance of the SIM for protein/
protein interactions, while covalent attachment of SUMO to its target
lysine seems to be of minor relevance. Accordingly, coexpression ofFig. 6. The SIM is not required for the SUMOylation of HIPK2 but controls its activity. (A) HE
tagged SUMO1-3 as shown. Equal amounts of protein contained in cell lysates were analyzed
to the SUMOylated form. (B) H1299 cells were transfected with a p53-dependent reporter ge
were lysed and either analyzed for protein expression and p53 serine 46 phosphorylation (low
independent experiments. (C) HEK293T cells were transfected with a reporter gene under th
the indicated HIPK2 variants. Induction of transcription and protein expression were measu
Siah2 with the indicated HIPK2 mutants in the presence of MG-132, cell lysates were prepar
bands corresponding to phosphorylated Siah2. Phosphorylation of Siah2 was additionally rev
was ensured using Flag antibodies. The positions of phosphorylated and hyperphosphorylate
with the indicated HIPK2 variants. Indirect immunoﬂuorescence was used to reveal the intHIPK2 K25A with a Pc2 variant mutated in the main SUMOylation site
(Pc2 K492R) still allowed large colocalization between both proteins
(Supplementary Fig. 4). The model shown in Fig. 5A implies that
overexpression of a SUMO variant defect for the attachment to its
target lysine should be able to compete with the endogenous SUMO
for SIM binding and thus disrupt a fraction of SUMO/SIM interactions.
We tested this hypothesis experimentally and measured HIPK2
localization in the presence of overexpressed wild-type SUMO-1
and a point mutant changed in the two C-terminal glycines needed for
coupling to the target lysine. While the wild-type HIPK2 localized to
nuclear bodies and showed colocalization with SUMO-1, the SUMO-1K293T cells were transfected to express Flag-HIPK2 or HIPK2 ΔSIM together with GFP-
by immunoblotting for the occurrence of a slower migrating HIPK2 form corresponding
ne and expression vectors for p53, HIPK2 and HIPK2 variants as shown. After 36 h, cells
er) or for luciferase activity (upper). Error bars show the standard deviations from four
e control of 5 binding sites for IPF/PDX together with expression vectors for IPF/PDX and
red as in (B). (D) Cells were transfected with expression vectors encoding Flag-tagged
ed and separated by extended SDS-PAGE in order to facilitate the detection of upshifted
ealed by phosphospeciﬁc antibodies, and comparable expression of the HIPK2 mutants
d Siah2 are indicated. (E) U2OS cells were transfected to express GFP-tagged p66β along
racellular localization of both proteins.
Fig. 6 (continued).
294 L. de la Vega et al. / Biochimica et Biophysica Acta 1813 (2011) 283–297GG/AA mutant caused mislocalization of a substantial fraction of
HIPK2 which also occurred in the cytosol (Fig. 5D).
3.5. A functional role of SUMO/SIM interactions for HIPK2 activity
SUMO/SIM interactions control several parameters including
SUMO E3 ligase activity of Pc2 and also selection of the adequate
SUMO paralogue. For example, non-covalent interactions betweenSUMO-2/3 and the Bloom syndrome protein are required for
preferential modiﬁcation by SUMO-2/3 [34]. To test whether the
SIM in HIPK2 has any inﬂuence on the SUMOylation efﬁciency and
SUMO isoform selection, HIPK2 or HIPK2 ΔSIM were expressed alone
or with GFP-tagged versions of all three major SUMO isoforms.
Coexpression of HIPK2 with GFP-tagged SUMO-1 resulted in the
occurrence of a slower migrating band corresponding to the expected
molecular weight of the SUMOylated kinase, while SUMO-2 and
Fig. 6 (continued).
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remained without impact on the HIPK2 modiﬁcation by SUMO-1,
indicating that a functional SIM is not required for this process.
As HIPK2 regulates the activity of several transcription factors, it
was interesting to compare the HIPK2 mutants for their ability to
regulate gene expression. HIPK2 and variants thereof were compared
for their ability to phosphorylate p53 and to trigger its transcriptional
activity. To address this question, p53-deﬁcient H1299 cells were
transfected with a p53-dependent reporter gene and expression
vectors for p53, HIPK2 and its variants. While p53 serine 46
phosphorylation was roughly comparable between HIPK2 and its
mutants, deletion of the SIM signiﬁcantly impaired the ability of
HIPK2 to trigger p53-dependent transcription (Fig. 6B). To investigate
whether HIPK2 ΔSIM also shows altered activities towards other
transcription factors, cells were transfected with a IPF1/PDX-
dependent reporter construct along with an expression vector for
IPF1/PDX and various HIPK2 expression constructs. Analysis of
luciferase activity showed the importance of HIPK2 kinase function
for its ability to trigger IPF1/PDX activity (Fig. 6C). While the activity
of HIPK2 K25Awas similar to that of the wild-type kinase, deletion of
the SIM allowed for an augmented activity. These results suggest
that the SIM can be either important for HIPK2 function (as is the
case for p53) or even play an inhibitory role, which is in line with thereported role of SUMO in transcriptional repressor complexes [35]. Is
there any role of intramolecular SUMO/SIM interactions that may
determine the activity of HIPK2? To explore this possibility, HIPK2
mutants were compared for their ability to phosphorylate a cytosolic
substrate protein. The best known cytosolic HIPK2 substrate is Siah2,
which gets phosphorylated by HIPK2 at many sites including
threonine 26, serine 28, and serine 68 [16]. Lysates from cells
transfected to coexpress Siah2 and various HIPK2 mutants were
analyzed for Siah2 phosphorylation in two ways: extended gel
electrophoresis was performed to detect phosphorylated and thus
upshifted Siah2 bands as described [16] and in parallel serine 28
phosphorylation was detected using a phospho-speciﬁc antibody.
Mutation of lysine 25 or deletion of the SIM resulted in a strongly
elevated kinase function of HIPK2 (Fig. 6D), a result that is
compatible with the idea that intramolecular SUMO/SIM interac-
tions renders HIPK2 more active.4. Discussion
Using a point mutation strategy, this study identiﬁes two NLS
sequences for HIPK2 at position 795 to 798 (NLS1) and 825 to 828
(NLS2) and also a SIM between 880 and 890.
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the region between 629 and 859 for nuclear localization of this kinase
[25]. The same paper also showed that the SRS can be separated from
other regions in HIPK2 that still allow for nuclear localization. The SIM
is entirely contained in the SRS region (860–967) identiﬁed in this
previous study, thus providing evidence that the speckle retaining
function of this region is attributable to a functional SIM. Mutation of
only one amino acid in NLS2 is sufﬁcient to interfere with nuclear
localization, while the inactivation of NLS1 required the mutation at
two residues, which might be an indication that NLS2 is of major
importance. While most HIPK2 occurs in nuclear domains, some cells
contain signiﬁcant amounts of the kinase in the cytosol. A possible
molecular mechanism responsible for differential localization may
employ high-mobility group protein A1, as increased expression of
this protein leads to increased cytosolic localization of HIPK2 [21]. It
would thus be interesting to know whether the reported interaction
between HIPK2 and high-mobility group A1 affects the accessibility of
the HIPK2 NLS regions. Mutation of each individual NLS results in the
cytosolic localization of HIPK2 without excluding it from the nucleus
where a signiﬁcant fraction of the kinase is still detectable in HIPK
domains. This residual localization may well be due to SUMO/SIM
interactions that mediate trapping of HIPK2 in nuclear speckles upon
binding to other nuclear proteins such as Pc2 or PML. Mutation of the
HIPK2 SIM did not only reduce binding to Pc2 and PML but also
prohibited recruitment of the kinase to PML-NBs, which also depend
on a functional SIM in the PML protein [36].
Given broad spectrum of SUMOylated proteins, it is reasonable to
assume that the HIPK2 SIM will allow for assembly with even more
SUMOylated proteins. Along this line, we found the relevance of the SIM
for coupling to p66β (Fig. 6E), a potent transcriptional repressor that
interacts with the methyl-CpG-binding domain (MBD) proteins MBD2
andMBD3 [28]. These observations suggest that SUMO/SIM interactions
contribute to the stable assembly of nuclear bodies hosting macromo-
lecular multi-protein complexes. These aggregates are characterized by
macromolecular crowding and individual proteins are integrated into
multi-protein networks. In such a situation with an extremely slow
diffusion, the deconjugation of SUMO from an individual protein would
still retain it in the protein complex due to SUMO/SIMmeshworks with
neighboring proteins. This concept also integrates the ﬁnding of normal
speckled localization of SUMOylation-deﬁcient HIPK2 and Pc2 point
mutants (Supplementary Fig. 4), while inactivation of the HIPK2 SIM
causes delocalization from HIPK domains. Depending on the cellular
context, the HIPK2 SIM may serve different functions. On one hand, it
can lead to transcriptional repression, as the SUMO/SIM system is
known to recruit repressor complexes and histone deacetylases [35]. On
the other hand, it allows cross-coupling and binding to other proteins
such as Pc2 and PML, thus enabling protein/protein interactions and
signal transmission. An intriguing possibility is the potential occurrence
of intramolecular SUMO/SIM interactions, which is supported by the
observation of enhanced Siah2 phosphorylation by HIPK2 K25A.
While SUMO/SIM interactions are an important glue that enhances
protein/protein afﬁnities, they do not allow to explain the speciﬁcity of
protein/protein interactions, which rely on direct contacts between the
proteins. Regulation of protein/protein afﬁnities by the SUMO/SIM
systems is thus a versatile tool to control the strength of protein/protein
interaction networks. This raises the need to regulate SUMOylation,
which can be achieved by several ways.We have previously shown that
activation of HIPK2 by genotoxic stress allows for HIPK2-mediated
phosphorylation of Pc2 at threonine 495, which in turn enhances its
SUMO E3 ligase activity towards HIPK2 [24]. This mechanism may also
explain that loss of HIPK2 kinase function results in nucleoplasmic
localization of HIPK2, as a kinase inactive HIPK2 point mutant is not
efﬁciently SUMOylated [24]. But also the deconjugation of SUMO can be
a regulated process. Previous studies showed that deconjugation of
SUMO from HIPK2 can be mediated by the isopeptidases SENP1
(sentrin-speciﬁc protease 1) and the SENP2 splice form SuPr-1[22,37]. The regulation of these enzymes is not well explored, but one
clue that may allow their differential activity is their distinct
intracellular localization. SENP1 shuttles between the cytosol and the
nucleus, while SuPr-1 localizes to PML-NBs. Another potential layer of
regulation comes from experiments describing the regulation of SUMO/
SIM afﬁnities by phosphorylation. As exempliﬁed by PIAS1 and PML,
phosphorylation of amino acids contained in the SIM adds negative
charge and thus increases binding afﬁnities. Thus itwould be interesting
to study potential phosphorylation of serines and the threonine
contained in the HIPK2 SIM.
5. Conclusions
This study allowed to map two independent nuclear localization
signals in HIPK2 and to reveal the importance of a C-terminal SIM for its
localization to nuclear speckles and its uptake in PML-NBs. These data
also show that SUMO/SIM interactions function as amolecular adhesive
that serves to enhance protein/protein interaction networks and to
control various HIPK2 functions. Thus the regulation of SUMO/SIM
interactions, as it occurs by HIPK2-dependent control of Pc2 activity,
allows to regulate localization and activity of this tumor suppressor
kinase.
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